Labs / ADME, DMPK & toxicology
Maxion® Therapeutics
Cambridge, United Kingdom · maxiontherapeutics.com
On your own
Free. Their own form.
Through Midgard
Midgard sends your request to the lab and keeps the order's messages, papers and payments in one place. Free to ask. 1% platform fee if you keep the order on Midgard.
Maxion® Therapeutics develops protein therapeutics based on its KnotBody® technology for ion channel- and GPCR-driven diseases. It is based in Cambridge, United Kingdom, and is led by a management team including CEO Arndt Schottelius, co-founder and CTO John McCafferty, and co-founder and CSO Aneesh Karatt-Vellatt.
Their website has a general contact form; we send your quote request through it.
What they offer
KnotBody® protein therapeutic discovery
Develops first-in-class and best-in-class protein therapeutics using KnotBody® technology for previously untreatable ion channel and GPCR-driven diseases.
What they work on
- Modalities
- Small molecule, Antibody
- Therapeutic areas
- chronic pain, autoimmunity, cardiovascular disease, ion channel diseases, GPCR-driven diseases
- Sites
- Cambridge, United Kingdom
Public records
- Ownership
- MAXION THERAPEUTICS LIMITED · GB GLEIF
Similar labs. Sparx BIO, Aclairo Pharmaceutical Development Group, Inc., ACM Global Laboratories, Allumiqs
Found in a contract services directory. Listing built from maxiontherapeutics.com. Work here? Claim this listing.